Skip to content
Medxy AI Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • ARDS
Fewer Post‑Traumatic ARDS Cases but Rising Mortality: A 2007–2019 NTDB Cohort Analysis
Posted inCritical Care news Respiratory

Fewer Post‑Traumatic ARDS Cases but Rising Mortality: A 2007–2019 NTDB Cohort Analysis

Posted by MedXY By MedXY 12/09/2025
A 2007–2019 National Trauma Data Bank analysis found ARDS incidence among ventilated trauma patients fell substantially, yet ARDS remained independently associated with increased 30‑day mortality and crude ARDS mortality rose to nearly 30%. Modifiable patient- and center-level factors deserve attention.
Read More
Prolonged Prone Positioning in ARDS: Current Evidence Is Inconclusive — No Clear Mortality or Safety Benefit
Posted inCritical Care news Respiratory

Prolonged Prone Positioning in ARDS: Current Evidence Is Inconclusive — No Clear Mortality or Safety Benefit

Posted by MedXY By MedXY 11/11/2025
A systematic review and meta-analysis found no clear mortality, oxygenation, or safety benefit for prolonged prone positioning (≥24 h) in ARDS; evidence is low to very low certainty and does not support routine use outside clinical trials.
Read More
Circulating Endothelial Transcriptomic Signatures Predict Worse Outcomes in COVID-19, Respiratory Failure and ARDS
Posted inCritical Care news Respiratory

Circulating Endothelial Transcriptomic Signatures Predict Worse Outcomes in COVID-19, Respiratory Failure and ARDS

Posted by MedXY By MedXY 11/07/2025
Transcriptomic deconvolution of blood identifies elevated circulating endothelial signatures (ECS%) that associate with higher 28‑day mortality and worse respiratory trajectories in pediatric respiratory failure and adults hospitalized with COVID‑19.
Read More
Trunk Inclination Changes Worsen Compliance and Raise PaCO2 in Obese ARDS Patients: Clinical Implications from a Seven-Study Pooled Analysis
Posted inCritical Care news Respiratory

Trunk Inclination Changes Worsen Compliance and Raise PaCO2 in Obese ARDS Patients: Clinical Implications from a Seven-Study Pooled Analysis

Posted by MedXY By MedXY 11/07/2025
A secondary analysis of 159 mechanically ventilated ARDS patients shows that increasing trunk inclination reduces respiratory system, lung, and chest wall compliance—especially in patients with obesity—and is associated with increased PaCO2 only in the obese subgroup.
Read More
Inhaled PEG‑Adrenomedullin in ARDS: Safe but Ineffective — Phase 2 RCT Stopped for Futility
Posted inCritical Care news Respiratory

Inhaled PEG‑Adrenomedullin in ARDS: Safe but Ineffective — Phase 2 RCT Stopped for Futility

Posted by MedXY By MedXY 11/07/2025
A multicentre randomized Phase 2a/b trial found inhaled pegylated adrenomedullin (PEG‑ADM) well tolerated in ventilated ARDS patients but without improvement in ventilator‑free survival or a composite clinical utility index; the study was stopped early for futility.
Read More
  • Beyond Nodal Status: A New Risk Score Predicts Recurrence in Lymph Node-Negative Pancreatic Neuroendocrine Tumors
  • Breaking the Data Silos: Why Sharing Clinical Trial Biospecimens Is Non-Negotiable for Cancer Care
  • Pathologic Response Predicts Disease-Free Survival in Neoadjuvant Immunotherapy for Mucosal HNSCC
  • Preoperative Cardiovascular Risk Does Not Dictate RAS Inhibitor Management: Insights from the STOP-or-NOT Trial
  • Diabetes, Obesity, and Early Rhythm Control in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Pediatrics Physical Activity Pregnancy prevention prostate cancer public health randomized clinical trial randomized controlled trial randomized trial screening SGLT2 inhibitors targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top
Sign in